Bullous pemphigoid treated with intravenous immunoglobulin
Bullous pemphigoid (BP) is a blistering autoimmune disease that primarily affects elderly patients who commonly present with comorbidities. Side effects from long-term treatment with conventional cytotoxic and immunosuppressive agents may increase morbidity and mortality in this patient population....
Saved in:
Main Authors: | Papapit Tuchinda, Simon Ritchie, Anthony A. Gaspari |
---|---|
Other Authors: | University of Maryland, Baltimore |
Format: | Article |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/34633 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Prevalence and clinical features of thai patients with bullous pemphigoid
by: Kanokvalai Kulthanan, et al.
Published: (2018) -
Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity
by: Papapit Tuchinda, et al.
Published: (2018) -
Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus
by: Kumutnart Chanprapaph, et al.
Published: (2022) -
Bullous Pemphigoid in an Infant: A Case Report and Literature Review
by: Wanee Wisuthsarewong, et al.
Published: (2018) -
Risk of venous thromboembolism in patients with bullous pemphigoid: A systematic review and meta-analysis
by: Patompong Ungprasert, et al.
Published: (2019)